Franz M Gerner

Title: Franz M Gerner: Innovator in Recombinant AAV Production

Introduction

Franz M Gerner is a notable inventor based in Rockville, MD (US), recognized for his contributions to the field of recombinant Adeno-Associated Virus (rAAV) production. With a total of 3 patents to his name, Gerner has made significant strides in improving methods for producing rAAV particles, which are crucial for gene therapy applications.

Latest Patents

Gerner's latest patents include innovative methods that enhance the production of rAAV particles. One of his patents, titled "Scalable method for recombinant AAV production," outlines improved techniques for culturing cells capable of producing rAAV particles. This method involves the use of a histone deacetylase (HDAC) inhibitor, which has been shown to increase the yield of rAAV particles. Another significant patent, "Scalable clarification process for recombinant AAV production," presents scalable methods for clarifying compositions that contain rAAV particles and impurities, further optimizing the production process.

Career Highlights

Franz M Gerner is currently associated with Regenxbio Inc., a company that focuses on gene therapy and the development of innovative treatments. His work at Regenxbio has positioned him as a key player in the advancement of rAAV technology, contributing to the company's mission of providing transformative therapies for patients.

Collaborations

Throughout his career, Gerner has collaborated with talented individuals such as Claire G Zhang and Shaojie Weng. These collaborations have fostered a productive environment for innovation and have led to the development of groundbreaking technologies in the field of gene therapy.

Conclusion

Franz M Gerner's contributions to the field of recombinant AAV production highlight his role as an influential inventor. His innovative patents and work at Regenxbio Inc. continue to pave the way for advancements in gene therapy, ultimately benefiting patients in need of effective treatments.